The stock of Stryker Corporation (NYSE:SYK) is a huge mover today! About 394,408 shares traded hands. Stryker Corporation (NYSE:SYK) has risen 3.14% since April 26, 2016 and is uptrending. It has underperformed by 2.12% the S&P500.
The move comes after 7 months positive chart setup for the $43.52B company. It was reported on Nov, 29 by Barchart.com. We have $124.23 PT which if reached, will make NYSE:SYK worth $3.05 billion more.
Analysts await Stryker Corporation (NYSE:SYK) to report earnings on January, 24. They expect $1.76 EPS, up 12.82% or $0.20 from last year’s $1.56 per share. SYK’s profit will be $659.73 million for 16.49 P/E if the $1.76 EPS becomes a reality. After $1.39 actual EPS reported by Stryker Corporation for the previous quarter, Wall Street now forecasts 26.62% EPS growth.
Stryker Corporation (NYSE:SYK) Ratings Coverage
Out of 19 analysts covering Stryker Corporation (NYSE:SYK), 11 rate it a “Buy”, 2 “Sell”, while 6 “Hold”. This means 58% are positive. $130 is the highest target while $88 is the lowest. The $109.83 average target is -5.40% below today’s ($116.1) stock price. Stryker Corporation has been the topic of 25 analyst reports since July 27, 2015 according to StockzIntelligence Inc. Goldman Sachs downgraded the shares of SYK in a report on Friday, November 13 to “Neutral” rating. The rating was initiated by Sterne Agee CRT with “Neutral” on Wednesday, November 4. The stock of Stryker Corporation (NYSE:SYK) has “Neutral” rating given on Thursday, March 17 by Nomura. The stock of Stryker Corporation (NYSE:SYK) has “Buy” rating given on Wednesday, April 27 by Sterne Agee CRT. Argus Research maintained Stryker Corporation (NYSE:SYK) rating on Wednesday, August 5. Argus Research has “Buy” rating and $120 price target. The rating was initiated by UBS with “Neutral” on Tuesday, September 22. BMO Capital Markets downgraded Stryker Corporation (NYSE:SYK) on Monday, December 14 to “Underperform” rating. Needham downgraded Stryker Corporation (NYSE:SYK) on Monday, September 28 to “Hold” rating. The stock of Stryker Corporation (NYSE:SYK) earned “Buy” rating by Stifel Nicolaus on Wednesday, August 12. The stock of Stryker Corporation (NYSE:SYK) earned “Buy” rating by SunTrust on Friday, October 14.
According to Zacks Investment Research, “Stryker Corporation develops, manufactures, and markets specialty surgical and medical products, including orthopaedic implants, bone cement, trauma systems used in bone repair, powered surgical instruments, endoscopic systems, craniomaxillofacial fixation devices, specialty surgical equipment used in neurosurgery and patient care and handling equipment for the global market and provide outpatient physical and occupational rehabilitation services.”
Insitutional Activity: The institutional sentiment decreased to 0.79 in 2016 Q2. Its down 0.14, from 0.93 in 2016Q1. The ratio dropped, as 41 funds sold all Stryker Corporation shares owned while 325 reduced positions. 61 funds bought stakes while 280 increased positions. They now own 279.01 million shares or 2.26% less from 285.46 million shares in 2016Q1.
Bb&T, a North Carolina-based fund reported 39,509 shares. Los Angeles Cap Mngmt & Equity Inc, a California-based fund reported 108,703 shares. Ghp Invest Advisors reported 24,696 shares or 0.64% of all its holdings. Tctc Holding Co accumulated 20,476 shares or 0.17% of the stock. Pnc Financial Svcs Grp Incorporated, a Pennsylvania-based fund reported 1.02 million shares. Bryn Mawr Trust has 0.93% invested in the company for 122,470 shares. Diamond Hill Cap Mngmt holds 0.67% of its portfolio in Stryker Corporation (NYSE:SYK) for 883,282 shares. Evercore Wealth Mgmt Ltd Limited Liability Company reported 36,996 shares or 0.2% of all its holdings. Guardian Capital Limited Partnership accumulated 65,833 shares or 0.13% of the stock. Hall Laurie J Trustee has 2.95% invested in the company for 36,942 shares. Chesley Taft And Assocs Ltd Liability Corp has invested 1.39% of its portfolio in Stryker Corporation (NYSE:SYK). The Netherlands-based Robeco Institutional Asset Bv has invested 0.1% in Stryker Corporation (NYSE:SYK). Livforsakringsbolaget Skandia Omsesidigt has invested 0.18% of its portfolio in Stryker Corporation (NYSE:SYK). Centurylink Investment Mgmt holds 5,237 shares or 0.22% of its portfolio. The Massachusetts-based Adage Capital Grp Llc has invested 0.09% in Stryker Corporation (NYSE:SYK).
Insider Transactions: Since May 31, 2016, the stock had 2 insider buys, and 63 selling transactions for $85.16 million net activity. 12,000 shares were sold by STRYKER RONDA E, worth $1.38 million on Tuesday, August 9. The insider Owen Katherine Ann sold $808,960. Becker Yin C also sold $129,987 worth of Stryker Corporation (NYSE:SYK) shares. Shares for $1.10M were sold by Scannell Timothy J on Tuesday, May 31. $5,308 worth of shares were bought by Doliveux Roch on Friday, July 29. COX HOWARD E JR sold $1.11 million worth of stock or 9,448 shares. $3.04M worth of Stryker Corporation (NYSE:SYK) shares were sold by Lobo Kevin.
SYK Company Profile
Stryker Corporation (Stryker), incorporated on February 20, 1946, is a medical technology company. The Firm operates through three divisions: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Firm offers its products to doctors, hospitals and other healthcare facilities. The Company’s products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment, and neurosurgical, neurovascular and spinal devices, as well as other medical device products used in a range of medical specialties. The Company’s products are sold in approximately 100 countries through the Company-owned sales subsidiaries and branches, as well as third-party dealers and distributors. The Firm offers a 1588 advanced imaging modalities (AIM) platform, which is designed for optimum visualization across surgical specialties.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.